ArticleResearch (Washington, D.C.)2026
Physics-Informed Artificial Intelligence Design of Picomolar Nanobodies Enables Deep Tumor Penetration and High-Contrast Imaging.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical utility of nanobodies in solid tumor therapy is constrained by a fundamental biophysical trade-off: rapid renal clearance necessitates half-life extension, which in turn demands ultrahigh affinity to prevent dissociation from the target under systemic washout conditions. While generative artificial intelligence has substantially advanced structure prediction, it often fails to resolve the subtle energetic frustrations at protein-protein interfaces required for affinity maturation. Here, we present a physics-informed artificial intelligence framework that integrates AlphaFold 3 structural priors with molecular dynamics simulations to rationally design a picomolar anti-carcinoembryonic antigen nanobody. By employing variable dielectric molecular mechanics/generalized Born surface area decomposition, we identified interfacial residues that were structurally permissible but thermodynamically suboptimal. We subsequently constructed a focused library to resolve these bottlenecks through electrostatic optimization, desolvation penalty minimization, and van der Waals packing refinement. This strategy achieved a 99% binding positivity rate and yielded variants with picomolar affinity (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.